Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab deruxtecan in HER2-overexpressing metastatic colorectal cancer
NCT04744831Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2021
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of trastuzumab deruxtecan in colorectal cancer (CRC), sponsored by Daiichi Sankyo Co., Ltd.. Started Mar 2021; status: completed.
02
Drugs
trastuzumab deruxtecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04744831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04744831.